Novavax Inc logo

NVAX - Novavax Inc Share Price

$201.45 6.8  3.5%

Last Trade - 6:55pm

Large Cap
Market Cap £10.46bn
Enterprise Value £10.28bn
Revenue £345.9m
Position in Universe 750th / 6848
Unlock NVAX Revenue
Relative Strength (%)
1m -7.70%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -41.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
36.3 15.4 31.2 34.3 18.7 475.6 4,065 4,541 +67.3%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, Novavax,Inc. revenues increased from $18.7M to $475.6M. Net lossincreased from $132.7M to $418.3M. Revenues reflect Grantand other increase from $11.2M to $258.4M, Governmentcontract increase from $7.5M to $217.2M. Higher net lossreflects Research and development - Balancing increase from$105.4M to $691.1M (expense), Stock-based Compensation inSGA increase from $8.6M to $72.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for NVAX
Graphical History


NVAX Revenue Unlock NVAX Revenue

Net Income

NVAX Net Income Unlock NVAX Revenue

Normalised EPS

NVAX Normalised EPS Unlock NVAX Revenue

PE Ratio Range

NVAX PE Ratio Range Unlock NVAX Revenue

Dividend Yield Range

NVAX Dividend Yield Range Unlock NVAX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
NVAX EPS Forecasts Unlock NVAX Revenue
Profile Summary

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated June 18, 1987
Public Since September 11, 2001
No. of Shareholders: 129
No. of Employees: 791
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 73,858,882
Free Float (0.0%)
Eligible for
NVAX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for NVAX
Upcoming Events for NVAX
Friday 25th June, 2021 Estimate
Novavax Inc Annual Shareholders Meeting
Frequently Asked Questions for Novavax Inc
What is the Novavax Inc share price?

As of 6:55pm, shares in Novavax Inc are trading at $201.45, giving the company a market capitalisation of £10.46bn. This share price information is delayed by 15 minutes.

How has the Novavax Inc share price performed this year?

Shares in Novavax Inc are currently trading at $201.45 and the price has moved by 1.00k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Novavax Inc price has moved by 0.661k% over the past year.

What are the analyst and broker recommendations for Novavax Inc?

Of the analysts with advisory recommendations for Novavax Inc, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Novavax Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Novavax Inc next release its financial results?

Novavax Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Novavax Inc dividend yield?

Novavax Inc does not currently pay a dividend.

Does Novavax Inc pay a dividend?

Novavax Inc does not currently pay a dividend.

When does Novavax Inc next pay dividends?

Novavax Inc does not currently pay a dividend.

How do I buy Novavax Inc shares?

To buy shares in Novavax Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Novavax Inc?

Shares in Novavax Inc are currently trading at $201.45, giving the company a market capitalisation of £10.46bn.

Where are Novavax Inc shares listed? Where are Novavax Inc shares listed?

Here are the trading details for Novavax Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: NVAX
What kind of share is Novavax Inc?

Based on an overall assessment of its quality, value and momentum, Novavax Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Novavax Inc share price forecast 2021?

Shares in Novavax Inc are currently priced at $201.45. At that level they are trading at 54.5% discount to the analyst consensus target price of 0.00.

Analysts covering Novavax Inc currently have a consensus Earnings Per Share (EPS) forecast of 19.823 for the next financial year.

How can I tell whether the Novavax Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novavax Inc. Over the past six months, the relative strength of its shares against the market has been 47.44%. At the current price of $201.45, shares in Novavax Inc are trading at 36.9% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Novavax Inc PE Ratio?

We were not able to find PE ratio data for Novavax Inc.

Who are the key directors of Novavax Inc?

Novavax Inc's management team is headed by:

Gary Evans - IND
Rajiv Modi - DRC
Stanley Erck - PRE
John Trizzino - EVP
James Young - CHM
Gregory Glenn - CEX
Richard Douglas - IND
John Herrmann - EVP
Rachel King - IND
Ben Machielse - EVP
Jill Hoyt - CHO
Frank Czworka - SVP
Gregg Alton - DRC
Gregory Covino - CFO
Rick Crowley - COO
Who are the major shareholders of Novavax Inc?

Here are the top five shareholders of Novavax Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.58% (5.60m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.09% (4.50m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 5.13% (3.79m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.43% (1.80m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 2.34% (1.73m shares)
Similar to NVAX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.